Soutullo, César

The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder

Faraone, S. V., Banaschewski, T., Coghill, D., Zheng, Y., Biederman, J., Bellgrove, M. A., Newcorn, J. H., Gignac, M., Al Saud, N. M., Manor, I., et al. (2021) · Neuroscience & Biobehavioral Reviews

Attention Deficit Hyperactivity DisorderAutism Spectrum Disorder Research

Cited by 1,545

ADHD management during the COVID-19 pandemic: guidance from the European ADHD guidelines group

Cortese, S., Asherson, P., Sonuga-Barke, E., Banaschewski, T., Brandeis, D., Buitelaar, J., Coghill, D., Daley, D., Danckaerts, M., Dittmann, R. W., et al. (2020) · The Lancet Child & Adolescent Health

Attention Deficit Hyperactivity DisorderCOVID-19 and Mental Health

Cited by 225

The management of ADHD in children and adolescents: bringing evidence to the clinic: perspective from the European ADHD Guidelines Group (EAGG)

Coghill, D., Banaschewski, T., Cortese, S., Asherson, P., Brandeis, D., Buitelaar, J., Daley, D., Danckaerts, M., Dittmann, R. W., Doepfner, M., et al. (2023) · European Child & Adolescent Psychiatry

Attention Deficit Hyperactivity DisorderChild and Adolescent Psychosocial and Emotional Development

Cited by 180

Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe

Coghill, D. R., Banaschewski, T., Nagy, P., Otero, I. H., Soutullo, C., Yan, B., Caballero, B., & Zuddas, A. (2017) · CNS Drugs

Attention Deficit Hyperactivity DisorderPharmaceutical studies and practices

Cited by 45

Lisdexamfetamine Dimesylate: A New Therapeutic Option for Attention-Deficit Hyperactivity Disorder

Steer, C., Froelich, J., Soutullo, C. A., Johnson, M., & Shaw, M. (2012) · CNS Drugs

Attention Deficit Hyperactivity DisorderPharmaceutical studies and practices

Cited by 30